Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Nutrients ; 14(11)2022 May 31.
Artículo en Inglés | MEDLINE | ID: mdl-35684106

RESUMEN

Cancer-associated cachexia (CAC) is the nutrition-independent loss of lean muscle and adipose tissues, and results in reduced chemotherapy effectiveness and increased mortality. Preventing adipose loss is considered a key target in the early stages of cachexia. Lipolysis is considered the central driver of adipose loss in CAC. We recently found that piceatannol, but not its analogue resveratrol, exhibits an inhibitory effect on lipolysis. The objective of this study was to investigate the role of piceatannol in cancer-associated lipolysis and cachexia-induced weight loss. Cancer cell-induced lipolysis in adipocytes was stimulated using cancer-conditioned media (CCM) or co-culture with human pancreatic cancer cells and the cachexia-associated cytokines TNF-α and interleukin-6 in 3T3-L1 adipocytes. C26 colon carcinoma-bearing mice were modeled using CAC in vivo. Piceatannol reduced cancer-associated lipolysis by at least 50% in both CCM and cytokine-induced lipolysis in vitro. Further gene and protein analysis confirmed that piceatannol modulated the stability of lipolytic proteins. Moreover, piceatannol protected tumor-bearing mice against weight-loss in early stages of CAC largely through preserving adipose tissue, with no effect on survival. This study demonstrates the use of a dietary compound to preserve adipose in models of early stage CAC and provides groundwork for further investigation of piceatannol or piceatannol-rich foods as alternative medicine in the preservation of body fat mass and future CAC therapy.


Asunto(s)
Neoplasias del Colon , Neoplasias , Tejido Adiposo/metabolismo , Animales , Caquexia/tratamiento farmacológico , Caquexia/etiología , Caquexia/metabolismo , Neoplasias del Colon/metabolismo , Medios de Cultivo Condicionados , Citocinas/metabolismo , Lipólisis , Ratones , Neoplasias/metabolismo , Polifenoles/farmacología , Estilbenos , Pérdida de Peso
2.
J Sci Food Agric ; 102(3): 1066-1075, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34309869

RESUMEN

BACKGROUND: Inflammation-related diseases present a significant public health problem. Ginger is a flavoring spice and medicinal herb with anti-inflammatory activity. This study investigated the preventive effects of ginger extract (GE) and its main bioactive component, 6-gingerol (6G), on lipopolysaccharide (LPS)-induced intestinal barrier dysfunction and liver injury in mice. RESULTS: GE and 6G were orally administered to mice for seven consecutive days before LPS administration. After 24 h, the mice were sacrificed. GE and 6G were found to significantly reverse LPS-induced inflammation in the mouse ileum by modifying the NF-κB pathway. They also alleviated apoptosis in the ileum by downregulating Bax and cytochrome c gene expression and by inhibiting the caspase-3 pathway. Through the aforementioned mechanisms, GE and 6G restored the intestinal barrier by increasing ZO-1 and claudin-1 protein expressions. Gut-derived LPS induced inflammation and apoptosis in the liver; these effects were markedly reversed through GE and 6G treatment. 6G was the most abundant component in GE, as evidenced through liquid chromatography-mass spectrometry, and accounted for >50% of total gingerols and shogaols in GE. CONCLUSION: The current results support the use of GE and 6G as dietary supplements to protect against gut-derived endotoxemia-associated inflammatory response and disorders. © 2021 Society of Chemical Industry.


Asunto(s)
Antiinflamatorios/administración & dosificación , Catecoles/administración & dosificación , Alcoholes Grasos/administración & dosificación , Enfermedades Intestinales/tratamiento farmacológico , Hepatopatías/tratamiento farmacológico , Extractos Vegetales/administración & dosificación , Zingiber officinale/química , Animales , Apoptosis/efectos de los fármacos , Humanos , Enfermedades Intestinales/inmunología , Enfermedades Intestinales/fisiopatología , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/inmunología , Mucosa Intestinal/lesiones , Lipopolisacáridos/efectos adversos , Hígado/efectos de los fármacos , Hígado/inmunología , Hígado/lesiones , Hepatopatías/inmunología , Hepatopatías/fisiopatología , Masculino , Ratones , Ratones Endogámicos ICR
3.
Nutrients ; 11(7)2019 Jul 23.
Artículo en Inglés | MEDLINE | ID: mdl-31340583

RESUMEN

(1) Background: Modern dietary patterns with a high intake of fat and fructose, as well as refined carbohydrates, closely relate to lipid/glucose metabolic disorders. The main objective of this study is to provide new thoughts in designing functional food with some lipid/glucose metabolism regulating effects for obese people. (2) Methods: The alleviating abilities of γ-oryzanol, phytosterol or ferulic acid-enriched wheat flour on lipid/glucose metabolic dysfunction were evaluated in male SD rats induced by a high-fat-fructose diet. The underlying mechanisms were clarified using western blot. (3) Results: In an in vitro cell model, γ-oryzanol, phytosterol and ferulic acid regulate lipid/glucose metabolism by increasing the phosphorylation of AMPK and Akt, and PI3K expression, as well as decreasing expressions of DGAT1 and SCD. The in vivo study shows that ferulic acid and γ-oryzanol-enriched flours are beneficial for managing body weight, improving glucose metabolism, hyperlipidemia and hepatic lipid accumulation. Phytosterol-enriched flour exerted remarkable effects in regulating hyperinsulinemia, insulin resistance and hyperuricemia. Western blot analysis of proteins from liver samples reveals that these enriched flours alleviated hepatic lipid accumulation and insulin resistance through their elevation in the phosphorylation of AMPK and Akt. (4) Conclusions: Our study indicates that these enriched flours can serve as a health-promoting functional food to regulate obesity-related lipid/glucose metabolic dysfunction in rats.


Asunto(s)
Alimentación Animal , Glucemia/metabolismo , Ácidos Cumáricos/administración & dosificación , Harina , Alimentos Fortificados , Lípidos/sangre , Enfermedades Metabólicas/prevención & control , Obesidad/prevención & control , Fenilpropionatos/administración & dosificación , Fitosteroles/administración & dosificación , Triticum , Animales , Biomarcadores/sangre , Ácidos Cumáricos/metabolismo , Azúcares de la Dieta , Modelos Animales de Enfermedad , Fructosa , Células Hep G2 , Humanos , Masculino , Enfermedades Metabólicas/sangre , Enfermedades Metabólicas/etiología , Obesidad/sangre , Obesidad/etiología , Fenilpropionatos/metabolismo , Fitosteroles/metabolismo , Ratas Sprague-Dawley , Transducción de Señal
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA